Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402]

Affiliations

¹ Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: mildred.iro@paediatrics.ox.ac.uk.
² Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
³ Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK.
⁴ Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK.
⁵ Bristol Children's Vaccine Centre, University of Bristol, Bristol, UK.
⁶ St Georges Vaccine Institute, St George's, University of London, London, UK.
⁷ Azienda Ospedaliero-Universitaria Maggiore della Carità, Clinica Pediatrica, Novara, Italy.
⁸ Pediatric Highly Intensive Care Unit, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
⁹ Vaccine Research Area, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain.
¹⁰ Charles University Prague, School of Medicine Hradec Kralove, Czech Republic.
¹¹ Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA.
¹² GSK Vaccines S.r.l., Siena, Italy.

Free article

Published Erratum

Mildred A Iro et al. Vaccine. 2017.

Free article

. 2017 May 31;35(24):3279.

doi: 10.1016/j.vaccine.2017.04.081. Epub 2017 May 5.

¹ Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: mildred.iro@paediatrics.ox.ac.uk.
² Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
³ Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK.
⁴ Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK.
⁵ Bristol Children's Vaccine Centre, University of Bristol, Bristol, UK.
⁶ St Georges Vaccine Institute, St George's, University of London, London, UK.
⁷ Azienda Ospedaliero-Universitaria Maggiore della Carità, Clinica Pediatrica, Novara, Italy.
⁸ Pediatric Highly Intensive Care Unit, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
⁹ Vaccine Research Area, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain.
¹⁰ Charles University Prague, School of Medicine Hradec Kralove, Czech Republic.
¹¹ Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA.
¹² GSK Vaccines S.r.l., Siena, Italy.

No abstract available

Erratum for

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, Bona G, Esposito S, Diez-Domingo J, Prymula R, Odueyungbo A, Toneatto D, Dull P, Pollard AJ; European Men B Vaccine Study Group. Iro MA, et al. Vaccine. 2017 Jan 5;35(2):395-402. doi: 10.1016/j.vaccine.2016.11.009. Epub 2016 Nov 30. Vaccine. 2017. PMID: 27914744 Clinical Trial.